Socio-economic impact of migraine and headaches in France;Impact socio-économique de la migraine et des céphalé es en France

CNS Drugs

Volumn 20, Issue SUPPL. 1, 2006, Pages 37-46

  Auray, Jean Paul ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ERGOT ALKALOID; SEROTONIN 1A AGONIST; TRIPTAN DERIVATIVE;

CONSULTATION; DAILY LIFE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FRANCE; HEADACHE; HEALTH CARE COST; HEALTH SURVEY; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; MIGRAINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS; ECONOMICS; INFORMATION PROCESSING; SICKNESS IMPACT PROFILE;

DATA COLLECTION; FRANCE; HEADACHE; HEALTH SURVEYS; HUMANS; MIGRAINE DISORDERS; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; SOCIOECONOMIC FACTORS;

EID: 33645525738     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Henry P, Duru G, Chazot G, Dartigues JF, et le GRIM. La migraine en France : étude épidémiologique, impact socio- économique et qualité de vie. John Libbey Edr., Eurotext, Paris 1993, 138p
2. Michel P, Auray JP, Chicoye A, et al. Prise en charge des migraineux en France : coût et recours aux soins - évaluation économique de la migraine en France. J Econom Méd 1993; 11: 71-80
3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8 (Suppl 7): 1-96
4. Legg RF, Sclar DA, Nemec NL. Cost-effectiveness of sumatriptan in a managed care population. Am J Man Care 1997; 3: 117-22
5. Solomon GD, Litaker DG. The impact of drug therapy on quality of life in headache and migraine. Pharmacoeconomics 1997; 11: 334-42
6. Richard A, Henry P, Chazot G, et al. Qualité de vie et migraine. Validation du questionnaire QVM en consultation hospitalière et en médecine générale. Thérapie 1993; 48: 89-96
7. Bateman DN. Triptans and migraine. Lancet 2000; 335: 860-1
8. Bosanquet N, Zammit-Lucia J. Migraine: prevention or cure? Br J Med Econ 1992; 2: 81-91
9. Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample survey. Headache 1992; 32: 223-8
10. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated withmigraine in a managed healthcare setting. Ann Pharmacother 1994; 28: 659-64
11. Henry P, Auray JP, Chazot G, et al. Prevalence and clinical characteristics of migraine in France. Neurology 2002; 59: 232-7
12. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 1996; 36: 538-41
13. Michel P, Pariente P, Duru G, et al. MIG ACCESS: A population-based, nationwide, comparative survey of access to care in migraine in France. Cephalalgia 1996; 16: 50-5
14. Michel P, Dartigues JF, Lindoulsi A, et al. Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache 1997; 37: 71-8
15. Michel P, Dartigues JF, Duru G, et al. Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort. Cephalalgia 1999; 19: 503-10